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Purpose: The aim of this prospective randomized study was to evaluate the relative risks and advantages of using the
Hemobahn graft for popliteal artery aneurysm (PAA) treatment compared with open repair (OR). The primary end point
was patency rate; secondary end points were hospital stay and length of surgical procedure.
Methods: The study was a prospective, randomized clinical trial carried out at a single center from January 1999 to
December 2003. Inclusion criteria were an aneurysmal lesion in the popliteal artery with a diameter >2 cm at the
angio-computed tomography (CT) scan, and proximal and distal neck of the aneurysm with a length of >1 cm to offer
a secure site of fixation of the stent graft. Exclusion criteria were age <50 years old, poor distal runoff, contraindication
to antiplatelet, anticoagulant, or thrombolytic therapy, and symptoms of nerve and vein compression. The enrolled
patients were thereafter prospectively randomized in a 1-to-1 ratio between OR (group A) or endovascular therapy (ET)
(group B). The follow-up protocol consisted of duplex ultrasound scan and ankle-brachial index (ABI) measured during
a force leg flexion at 1, 3, and 6 months. Group B patients underwent an angio-CT scan and plain radiography of the knee
with leg flexion (>120°) at 6 and 12 months, and then yearly.
Results: Between January 1999 and December 2003, 30 PAAs were performed: 15 OR (group A) and 15 ET (group B).
Bypass and exclusion of the PAA was the preferred method of OR; no perioperative graft failure was observed. Twenty
stent grafts were placed in 15 PAAs. Endograft thrombosis occurred in one patient (6.7%) in the postoperative period.
The mean follow-up period was 46.1 months (range, 12 to 72 months) for group A and 45.9 months (range, 12 to 65
months) for group B. Kaplan-Meier analysis showed a primary patency rate of 100% at 12 months for OR and 86.7% at
12 months with a secondary patency rate of 100% at 12 and 36 months for ET. No statistical differences were observed
at the log-rank test. The mean operation time (OR, 155.3 minutes; ET, 75.4 minutes) and hospital stay (OR, 7.7 days;
ET, 4.3 days) were statistically longer for OR compared with ET (P < .01).
Conclusion:We can conclude, with the power limitation of the study, that PAA treatment can be safely performed by using
either OR or ET. ET has several advantages, such as quicker recovery and shorter hospital stay. ( J Vasc Surg 2005;42:
185-93.)Popliteal artery aneurysms (PAAs), despite their rarity,
account for 70% to 80% of all peripheral artery aneu-
rysms.1-5 They occur more frequently in men, and about
half are bilateral and are accompanied by aortic or femoral
aneurysms.6-9 A PAA can be asymptomatic and is often
discovered by coincidence, or is symptomatic with acute
thrombosis or distal embolization; rupture is uncom-
mon.6-9 Asymptomatic and symptomatic aneurysms of 2
cm in diameter are considered candidates for elective sur-
gery.10
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doi:10.1016/j.jvs.2005.04.049The goals of surgical treatment for PAA are to isolate
and exclude the aneurysm, prevent distal embolization, and
allow effective revascularization. Limb salvage is low in
patients with symptomatic PAAs, particularly in those with
acute ischemia; it is higher for asymptomatic patients.11-13
Moreover, it is also argued that although long-term graft
patency may not be good, limb salvage is achieved if the
graft remains patent for 1 year.14
During recent years, endovascular surgery has be-
come a valid alternative to open repair. Particularly sig-
nificant progress has occurred in the endovascular treat-
ment of arterial aneurysms, especially of the abdominal
aorta. Potentially, PAAs are also treatable by an endovas-
cular procedure. The endovascular exclusion of PAAs, a
less invasive procedure compared with conventional sur-
gery, offers some advantages: lower blood loss, quicker
recovery, and shorter hospital stay; moreover, it permits
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access.
The main problem with PAA endovascular reconstruc-
tion is the availability of an endograft with the good flexi-
bility that is required for the close relation of the aneurysm
with the knee joint. The Hemobahn graft (W.L. Gore &
Assoc, Flagstaff, Ariz) is a self-expanding nitinol stent,
internally covered by an ultra-thin polytetrafluoroethylene
(PTFE) graft. As a result of a special nitinol stent design,
the Hemobahn offers good flexibility and radial stiffness.
Endovascular repairs for PAAs have been described by
several authors, but few reports have showed the safety and
efficacy of theHemobahn endograft in the treatment of this
type of aneurysm.15-17
The aim of this prospective randomized study was to
evaluate the relative risks and advantages of using the
Hemobahn graft for PAA treatment compared with surgi-
cal repair. The primary end points were primary and sec-
ondary patency rates; the secondary end points were hospi-
tal stay, length of surgical procedure, and any other local
complication. Our hypothesis was that ET of PAAs would
obtain better results compared with OR.
MATERIALS AND METHODS
Study design. The study, which was approved by the
ethics committee of our institution, was a prospective,
randomized clinical trial carried out at a single center from
January 1999 to December 2003. During the study period,
all patients with a diagnosis of PAA at the duplex scan
underwent an angio-computed tomography (CT) scan and
digital subtraction angiography (DSA) to define the aneu-
rysm extension and diameter, proximal and distal necks,
significant collateral vessels originating from the aneurysm,
and distal outflow.
Inclusion criteria were:
1. an aneurysmal lesion in the popliteal artery with a diam-






Mean age (range) 64.7 (51-84) 62.7 (51-81)
Smoking (%) 10 (66.7) 9 (60)
Diabetes mellitus (%) 2 (13.3) 2 (13.3)
Hypertension† (%) 10 (66.7) 7 (46.7)
CAD‡ (%) 4 (26.7) 5 (33.3)
Hypercholesterolemia (%) 4 (26.7) 4 (26.7)
COPD§ (%) 3 (20) 2 (13.3)
OR, Open repair; ET, endovascular treatment; CAD, coronary artery dis-
ease; COPD, chronic obstructive pulmonary disease.
*P values for all data are not significant.
†History of hypertension; patient taking at least one antihypertensive med-
ication.
‡History of myocardial infarction, angina or electrocardiographic sign of
myocardial ischemia.
§Defined as forced expiratory volume in 1 second (FEV1)1 or FEV1/FVC
(forced vital capacity) 75.eter of 2 cm at the angio-CT scan, and2. proximal and distal neck of the aneurysm with a length
of 1 cm to offer a secure site of fixation of the stent
graft.
Exclusion criteria were:
1. age 50 years old;
2. poor distal runoff, defined as a runoff score of 8
according to the system recommended by the Joint
Council of the Society for Vascular Surgery and the
International Society for Cardiovascular Surgery in
which a value of 1 represents optimal runoff and a value
of 10 absent runoff18;
3. a contraindication to antiplatelet, anticoagulant, or
thrombolytic therapy, and
4. symptoms of nerve and vein compression.
The enrolled patients were thereafter prospectively ran-
domized in a 1-to-1 ratio between open repair (OR)
(group A) or endovascular treatment (ET) (group B).
Patients with bilateral PAAs were enrolled in the study; the
second randomization was performed after a minimum of 3
months.
The randomization scheme was obtained by using
sealed opaque envelopes containing the indication to OR
or ET, that were put into a container in blocks of 10 (5 OR,
5 ET). The envelopes were extracted by the study control-
ler the day before the procedure was planned. Patients were
excluded from this study and therefore from randomization
if they declined to participate.
Before starting this study, we calculated the sample size
for each of the two randomized cohorts. A retrospective
review of our data concerning the results of 23 consecutive
PAAs treated with OR from January 1995 to December
1998 revealed a primary patency rate estimated with the
Kaplan-Mayer analysis of approximately 90%. From this
data, 302 patients (151 for each group) needed to be
enrolled to reveal a statistical difference at 1-year follow-up.
The main assumptions for this calculation were (1) the
1-year postoperative primary patency rate for the endovas-
cular repair was expected to be 95% and (2) the power of
the study was 80% at the .05 significance level by log-rank-
test. To enroll 302 patients, we estimated, on the basis of
our previous data, a period of 50 years would have been be
necessary to project this study. Nevertheless, we decided to
do it with a lower number of patients and the consequent
power limitation to test the safety and efficacy of ET for
PAA repair.
Patients. A total of 36 patients with a diagnosis of
PAA at the duplex ultrasound scan between January 1999
and December 2003 were considered for inclusion. Ten
(27.8%) were excluded because of age 50 years old in
two, poor distal run-off in four, proximal or distal neck with
a length of1 cm in another three, and symptoms of nerve
and vein compression in one. Twenty-six patients (4 with
bilateral PAAs) were randomized and assigned to the two
groups: group A, 15 patients for OR; and group B, 15
patients for ET. Two patients with bilateral PAAs were
assigned twice to group A and twice to both groups. The
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two groups are reported in Table I. The mean aneurysm
diameters and lengths were 35.8  12.3 mm and 10.3 
2.5 cm in group A, and 36.9 14.6 mm and 9.8 2.1.cm
in group B; they were saccular in 25 patients (83.3%) (13 in
group A, 12 in group B) and fusiform in five patients
(16.7%) (2 in group A, 3 in group B).
Stent-graft design.
Knee joint movements should be taken into account in
the endovascular treatment of PAAs. The ideal graft should
have good flexibility and resistance to external compression
so that occlusion and dislodgment are avoided. The He-
mobahn endoprosthesis was used for PAA treatment. The
Hemobahn is a self-expanding nitinol stent, internally cov-
ered by an ultra-thin PTFE graft; therefore, it is a biocom-
patible graft with a smooth, blood contact surface. In
addition, the special nitinol stent design, with a reduced
number of net junctions, allows the combination of flexi-
bility and radial stiffness, and the risk of kinking is mini-
mized. Hemobahn graft sizes range from 6 to 13 mm in
diameter and from 5 to 15 cm in length. Two clear linear
radiopaque markers along the graft allow an easy and exact
deployment in the target vessels. The stent graft is released
from the catheter as the containing lacing fibre is with-
drawn.
Endovascular technique. To permit a conversion to
OR in case of failure of ET, the endovascular procedure was
always performed in the operating room equipped with a
12-inch digital C-arm fluoroscopy unit (Series Eurocolum-
bus,Milano, Italy). Under locoregional anesthesia, an open
exposure of the femoral artery was performed to minimize
the risk of postoperative pseudoaneurysms only when the
device required a sheath 9F. Otherwise, the anterograde
percutaneous transfemoral puncture (18-gauge needle, 9F
sheath, and 150-cm  0.025-in Terumo guidewire) was
used.
The final choice of the stent length was confirmed by
the intraoperative angiography. Stent diameters must take
into consideration 20% to 25% oversizing. In choosing the
graft length, it is necessary to consider that the stent ex-
tremity should not land at the knee joint region or very
proximal to it (2 to 3 cm). Indeed, in this anatomic area, the
popliteal artery shows the maximal flexibility. For this rea-
son the endograft is always landed 2 to 3 cm over the knee
joint region.
Deployment begins with a steady, continuous pull of
the deployment knob. The stent graft is released from the
catheter as the lacing fibre is withdrawn, beginning from
the proximal end. Deployment is complete when the ex-
panded PTFE (ePTFE) lacing fiber is fully withdrawn from
the catheter. When significant sural branches are present,
coil embolization is required before stent introduction to
avoid the possibility of a type II endoleak (Fig 1). If
multiple stent grafts were required to seal the PAA, the
endografts were over lapped by at least 1 cm.19
The ET is considered successful when the PAA is
completely excluded with no signs of endoleaks at theintraoperative DSA. To verify the flexibility of the en-
dograft during the knee joint movement, an intraoperative
control DSA in lateral projection with a knee flexion120°
was performed (Fig 2). During this examination, a plain
radiograph was obtained to detect any deformity of the
structure of the endograft skeleton. The presence of an
endograft kinking resulting in a stenosis50% was consid-
ered positive and a criterion for surgical conversion.
Immediately after the procedure, antiplatelet therapy
was started with a single intravenous dose of 125 mg of
acetylsalicylic acid (ASA). Double antiplatelet therapy of
ASA (100 mg daily) plus ticlopidine (250 mg twice a day)
was started from the first postoperative day and continued
for 1 month; thereafter, the antiplatelet therapy was con-
tinued indefinitely with ASA (100 mg daily).
Open surgical technique. Direct endoaneurysmor-
rhaphy and bypass through a medial approach was the
preferred method of repair. Aneurysm excision as an alter-
native method was used in presence of small PAAs.
The bypass was performed with an end-to-side anasto-
mosis, preferably from the above-knee to the below-knee
popliteal artery. When the surgeon intraoperatively judged
that these arteries were not suitable to receive a vascular
anastomosis for the reason that their macroscopic aspect
was suspicious of a dysplastic degeneration and therefore at
risk of developing an anastomotic pseudoaneurysm, the
superficial first or, thereafter, the common femoral artery
were chosen as the inflow artery and the tibioperoneal
trunk as outflow artery.
Reversed great saphenous vein was the conduit of
choice. When the great saphenous vein was not available or
suitable for a bypass, preference was given to a 7-mm PTFE
graft. The bypass pathway was always anatomic. At dis-
charge, antiplatelet therapy was started with ASA (100 mg
daily) indefinitely.
Postoperative assessment and clinical data
follow-up examination. The follow-up protocol con-
sisted of a duplex ultrasound scan the day before discharge
to evaluate the graft patency, PAA exclusion, and the
ankle-brachial index (ABI), including during forced leg
flexion for group B patients. A reduction of ABI of 20%
from rest to leg flexion was considered a sign of endograft
kinking and an ET failure. The long-term follow-up was
based on clinical evaluation at 1 and 3 months, and every 6
months thereafter, with duplex ultrasound scan and ABI
measurements as previously described. In case of a sign of
50% restenosis at the duplex ultrasound scan, a DSA was
always performed. A restenosis of 50% was considered a
failure of the procedure.
To evaluate the patency and the stent skeleton integrity
and flexibility, the group B patients underwent an
angio-CT scan and plain radiograph of the knee joint with
forced leg flexion (120°) at 6 and 12 months and then
yearly.
Statistical analysis. Data were analyzed by using the
2 and the Fisher’s exact test for noncontinuous variables,
the Student’s t test for continuous variables, and the log-
rank test for Kaplan-Meier analysis.
t to e
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Between January 1999 and December 2003, 30 PAAs
(15 group A [OR] and 15 group B [ET]) were performed in
the cohort of 26 randomized patients (4 with bilateral PAAs).
Of the four patients with bilateral PAAs, two were random-
ized twice into group B, and the others were assigned to both
treatments. In the same period, another 16 patients under-
went 18 PAA corrections withORoutside of the study. Seven
of these patients were symptomatic: six had acute ischemia,
with an associated thrombosed PAA, and one patient had
critical leg ischemia with a patent fusiform PAA. Seven were
asymptomatic, presentingwith a poor distal runoff in four and
a distal neck length of 1 cm in three. Two patients were
excluded because they were 50 years old. The mean PAA
diameter of these patients was 3.4 0.4 cm.
The randomized patients represented the 65.2% of the
whole population that underwent PAA surgery at the De-
partment of Vascular Surgery, University of Padua.
There were no statistical differences between the demo-
graphic and clinical data of the two groups (Table I).
Open repair. Bypass and exclusion of the PAA with
Fig 1. A. Preoperative digital subtraction angiography
aneurismal sack of the poplital aortic aneurysm. B, Di
collateral vessel and endograft deployment (arrows poindirect endoaneurysmorrhaphy was the preferred method ofrepair; two (13.3%) had aneurysm excision. All patients had
their aneurysms repaired through a medial approach. OR
was performed under locoregional anesthesia in nine pa-
tients (60%) and general anesthesia in six (40%).
Reversed greater saphenous vein was the conduit of
choice. In four patients (26.7%), a prosthetic bypass
using ePTFE was performed for an unsuitable saphenous
vein. Inflow arteries varied among the study patients: the
common femoral artery was used in two (13.3%), the
superficial femoral artery in seven (46.7%), and the
above-knee PA provided inflow in six patients (40%).
The infrageniculate PA served as the outflow artery in
most cases. Four bypasses (26.7%) required a distal anas-
tomosis on the tibioperoneal trunk. No perioperative
graft failure was observed.
Endovascular treatment. ET of PAAs was performed
under locoregional anaesthesia in all cases. Twenty stent
grafts were placed in 15 PAAs: single devices were used in
10 aneurysms (66.7%), four (26.7%) required two stent
grafts, and one (6.7%) needed three. The mean diameter
and length of the implanted endografts were 7.9 1.1 mm
nstrates a collateral artery (arrow) originating from the
subtraction angiography after coil-embolization of the
ndograft location).demo
gitaland 11.4  3.2 cm.
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artery originating from the aneurysmal sac before the en-
dograft was placed to prevent a type II endoleak (Fig 1).
Aneurysmal exclusion was successful in all patients;
none required conversion to open surgery, no signs of
endoleak, and no endograft kinking during leg flexion were
observed at the intraoperative DSA (Fig 2).
Endograft thrombosis occurred in one patient (6.7%)
the day after the procedure, and it was related to an intra-
operative difficulty during the release of the distal part of
the endograft. The patient underwent successful intra-
arterial thrombolytic therapy, and thereafter, in an addi-
tional endovascular procedure, dilatation of the distal part
of the endograft re-established the patency of the stent-
graft.
The mean operation time (155.3 minutes for OR and
75.4 minutes for ET) and hospital stay (7.7 days for OR
and 4.3 days for ET) were statistically longer for group A
compared with group B (P  .01) (Table II).
Follow-up. The mean follow-up period was 46.1
months (range, 12 to 72 months) for group A and 45.9
Fig 2. Intraoperative digital subtraction angiography shows the
absence of endograft kinking during leg flexion (arrows point to
endograft location).months (range, 12 to 65 months) for group B.Two group A patients had a thrombosis of a ePTFE
femoropopliteal above-knee bypass and of a greater saphe-
nous vein femorotibioperoneal trunk bypass after 28 and
41 months. These patients were not considered for redo
surgery, because after the acute event, they presented with
lower limb claudication 500 m at the treadmill test.
The Kaplan-Meier analysis showed a primary patency
rate of 100% at 12 months, 90.9% at 36 months, and 81.8%
at 48 months (Fig 3). The clinical examination and the
duplex ultrasound scan performed during the follow-up
period showed the patency of the remaining bypasses.
The duplex ultrasound scan performed during the fol-
low-up period at 6 and 24 months revealed an asymptom-
atic restenosis of60% in the distal part of the endograft in
two group B patients, which DSA confirmed. These pa-
tients underwent an adjunctive endovascular procedure of
dilatation and deployment of a covered stent.
No signs of any type of endoleak, of aneurysmal sac
increasing (36.9  14.6 cm of diameter at the preoperative
angio-CT; 36.7  14.3 cm at angio-CT performed 12
months after the procedure), or of endograft kinking dur-
ing leg flexion were observed at the angio-CT or at the
plain radiograph performed during the follow-up period
(Fig 4). No significant variation of the ABI was observed
during the follow-up period between the rest position and
during forced leg flexion.
The primary patency rate was 86.7% at 12 months and
80% at 48months, with a secondary patency rate of 100% in
the same period (Figs 3 and 5). No statistical differences
were observed at the log-rank test for the primary patency
rate at 12 months and for the secondary patency between
the two groups at 36 months.
During the follow-up period, no deaths occurred in any
study patients.
DISCUSSION
Surgical treatment is indicated for all symptomatic or
complicated PAAs; controversy still exists over the optimal
management of asymptomatic PAAs. The recommendation
for the ideal treatment of these patients should be based on
the PAA’s natural history, but few data are available. Indi-
Table II. Procedural early results
Group A (OR) Group B (ET) P
Graft/endograft
occlusion
0 1 (6.7%) NS
Primary patency rate 100% 93.3% NS
Assisted patency rate — 100% NS
Limb salvage rate 100% 100% NS
Endoleaks — 0 NS
Mean operative time
(min)
75.4 (50-90)* 195.3 (120-255)* .01
Mean hospital stay
(days)
7.7 (7-11)* 4.3 (2-9)* .01
OR, Open repair; ET, endovascular treatment; NS, not significant.
*Range.cations for surgical intervention for asymptomatic PAAs
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cm, presence of thrombus, and poor runoff as risk factors
for complications in a group of 67 aneurysms treated
conservatively. Inahara and Toledo20 found no significant
correlation between aneurysmal sac diameter and the risk
for complication.
Many authors support surgical management as the
treatment of choice for asymptomatic PAAs for preventing
the ischemic complications from aneurysm embolism or
thrombosis and have achieved good surgical results in
terms of graft patency and limb salvage rate.11-14 The goals
of surgical treatment of PAAs are isolation of the aneurysm,
preventing distal embolization, and effective revasculariza-
tion. Five-year patency rates after surgical repair are 90%
for asymptomatic aneurysms and 75% in patients with
symptoms.11-14
Surgical mortality is low, ranging from 0% to 1% in
asymptomatic patients and 2.1% in acute patients.21 How-
ever, morbidity rates as high as 30% to 40% have been
reported, usually associated with wound complica-
tions.22-23
During recent years, endovascular surgery has become
a valid alternative to open repair. Particularly significant
progress has been observed in the endovascular treatment
of arterial aneurysms, especially of the abdominal aorta.
Potentially, PAAs are also treatable by an endovascular
approach. Moreover, compared with conventional surgical
treatment, the percutaneous endoluminal exclusion of
lower-extremity aneurysms as a minimally invasive proce-
dure offers some advantages, including lower blood loss,
quicker recovery, and shorter hospital stay.24-26
However, given the currently available stent-graft de-
signs, a percentage of aneurysms are not amenable to
percutaneous exclusion because of their position at the hip
or knee joint or at the branching of major vessels. Owing to
these limitations and the low incidence of femoropopliteal
aneurysms, the experience with endoluminal grafting for
aneurysm disease in this vessel segment has been limited
and largely ancedotal.19-28 Endovascular repair of a popli-
teal aneurysm was first described in 1994 by Marin et al,27
Fig 3. Kaplan-Meier analysis shows the primary paten
treatment (ET) (group B) at 6-month intervals. Standar
for ET (dashed line).who used a homemade stent graft consisting of a PTFEgraft and 2 Palmaz stents to seal the ends of the graft to the
vessel wall. In others reports, a variety of stents (Palmaz,
Cragg, Wallstent, or Gianturco) covered with PTFE, poly-
ester, polyurethane, or autologous vein were used.28-35
The early models—polyester and PTFE grafts sup-
ported by stents—were only marginally successful; but
more recently, encouraging preliminary results were
achieved with Wallstent-PTFE (Boston Scientific, Natick,
Mass) and the Wallgraft (Wallstent covered by a polyester
graft) for endoluminal treatment of popliteal aneurysms
with a secondary patency rate of 92% as described by
Howell et al17 in a series of 13 PAAs in which a secondary
patency rate of 92% was achieved.33-35 Tielliu et al15 have
also observed good early outcomes with the Hemobahn
stent-graft in 21 patients (23 procedures), with a cumula-
tive primary patency rate at 15 months of 75%. Gerasimidis
et al16 reported a series of 11 patients with 12 PAAs who
underwent ET using Hemobahn with a secondary patency
rate of 75% at 12 months.
All these studies, with the only exception being the one
of Tielliu et al,15 are retrospective, and especially, none
compare the results of ETwithOR. To our knowledge, our
study, which used a Hemobahn endograft for asymptom-
atic PAAs in a cohort of 26 patients, is the first prospective
randomized trial that compares OR versus ET. We chose
this device because of its technical characteristics: it is a
self-expanding nitinol stent, internally covered by an ultra-
thin PTFE graft with the special nitinol stent design that
reduces the number of net junctions, thus allowing the
combination of flexibility and radial stiffness and therefore
minimizing the risk of kinking during the knee joint flex-
ion.
This comparative trial was performed with the assump-
tion of a theoretic advantage in using the ET, but results
showed no statistical difference in primary and secondary
patency rates at 12 months between the two treatments.
The primary patency rate estimated with the Kaplan-Meier
analysis at 12 months was 100% for OR and 86.7% for ET,
the secondary patency rate at 36 months was 90.9% for OR
and 100% for ET. The primary patency rate for OR is
te for open repair (OR) (group A) and endovascular
r is 10% after 42 months for OR and after 24 monthscy ra
d errocomparable to those reported by other previous studies,
nt gr
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ET are slightly better rather than those from other studies
that reported a primary patency rate at 1 year ranging from
47% to 75%.15-16
This may be the result of patient selection and of the
postoperative therapy. In fact for this trial, only patients
with optimal anatomic characteristics for ET and especially
Fig 4. A. Angio-computed tomography scan and (B, C
show the flexibility and the integrity of theHemobahn stewith a runoff score of 8 according to the system recom-mended by the Joint Council of the Society for Vascular
Surgery and the International Society for Cardiovascular
Surgery were enrolled. Postoperative therapy based on a
single 125-mg intravenous dose of ASA immediately after
the surgical procedure, followed by double antiplatelet
therapy with ASA (100 mg daily) plus ticlopidine (250 mg
twice a day) continued for 1 month, differs from the other
n radiograms of the knee 24 months after the procedure
aft during rest position and forced knee flexion (120°).) plaireports in which a single oral dose of ASA (100mg daily) or
rd err
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rin were used.
As expected, statistical differences emerged for the
mean operation time (155.3 minutes for OR, 75.4 minutes
for ET) and, particularly, for the mean hospital stay (4.3
days for OR, 7.7 days ET) (P  .01). The ET permits a
quicker recovery and appears to have a great potential
advantage, not only for young patients that needed to
re-establish their normal activity quickly but also for older
patients in which a prolonged hospital stay is harmful.
No signs of endoleak were observed during the fol-
low-up period. This may be the result of our approach,
which included the embolization of any significant collat-
eral vessels originating from the aneurysmal sac and evalu-
ated at the preoperative DSA. No significant variation of
ABI was observed during the follow-up period between the
rest position and during forced leg flexion (120°). This is
an important goal; in fact, one of the most problematic
points of ET for PAAs is the great mobility of this anatomic
region and the possibility of kinking of the device.
Previous anatomic radiologic studies have found that
the distal part of the popliteal artery is relatively fixed at the
origin of the anterior tibial artery and at a more proximal
point that corresponds to the origin of the descending
genicular artery.36-38 Posterior movement of the popliteal
artery between these two fixed points does occur during
flexion, with the creation of flexures behind the posterior
articular structures of the knee.37,38 Moreover, it was
shown that knee flexion increases tortuosity of the supra-
articular popliteal artery, while the middle and the lower
part of the popliteal artery kept an even curve retracted
from the posterior surface of the joint. The tortuosity of the
popliteal artery is more pronounced in elderly patients and
did not disappear during knee extension.38 These findings
are similar to those observed in our study of the intraoper-
ative DSA and plain radiograph of the knee with forced leg
flexion, in which the tortuosity of the endograft was more
marked in the supra-genicular segment of the artery.
The Hemobahn endograft seems to be suitable for this
procedure, thanks to its particular structure that minimizes
the risk of kinking during knee joint movement; in fact in
Fig 5. Kaplan-Meier analysis of the secondary patenc
treatment (ET) (group B) at 6 months intervals. Standaour experience, no signs of any deformity of the structuralskeleton of the endograft was seen at the plain radiograph
of the knee during forced leg flexion (120°). Especially in
the supragenicular region of the popliteal artery, the most
critical region for tortuosity during knee flexion, the en-
dograft showed a good compliance. A longer follow-up is
required to analyze the risk of fracture and fabric disruption
of the stent graft that was designed to treat occlusions
rather than aneurysmal disease.
We can conclude, with the power limitation of the
study and waiting for a prospective randomized trial with a
larger number of patients and longer follow-up, that PAA
treatment can be safely performed using either OR or ET.
The choice of the ET has several advantages, such as
quicker recovery and shorter hospital stay, and should be
preferentially used in patients with a high surgical risk.
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